ALX ONCOLOGY HOLDINGS INC Cash Flow Statement
ALXO|3 years of annual SEC 10-K data (FY2020-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
ALX ONCOLOGY HOLDINGS INC used $89M in operating cash flow and negative free cash flow of $91M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Net Income | -$123.5M | -$19.2M | -$13.7M |
| Depreciation & Amortization | $342.0K | $429.0K | $431.0K |
| Operating Cash Flow | -$89.2M | -$14.2M | -$13.2M |
| Capital Expenditures | $1.4M | $353.0K | $653.0K |
| Free Cash Flow | -$90.7M | -$14.6M | -$13.8M |
| Share Buybacks | - | - | $6.0K |
| FCF Margin | - | -304.5% | -669.7% |